BA
SCLN

Boston Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Boston Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,373
Closed -$95K – 707
2015
Q4 		$95K Sell
10,373
-2,560
-20% -$21.4K ﹤0.01% 645
2015
Q3 		$90K Sell
12,933
-69,815
-84% -$598K ﹤0.01% 748
2015
Q2 		$813K Buy
82,748
+32,700
+65% +$298K 0.03% 325
2015
Q1 		$443K Sell
50,048
-5,013
-9% -$39.9K 0.02% 496
2014
Q4 		$482K Hold
55,061
– – 0.02% 348
2014
Q3 		$379K Hold
55,061
– – 0.02% 396
2014
Q2 		$290K Buy
55,061
+13,691
+33% +$66.6K 0.01% 491
2014
Q1 		$188K Sell
41,370
-830
-2% -$4.01K 0.01% 560
2013
Q4 		$213K Buy
42,200
+7,500
+22% +$36.1K 0.01% 554
2013
Q3 		$176K Buy
34,700
+11,900
+52% +$66.3K 0.01% 543
2013
Q2 		$113K Buy
+22,800
New +$108K 0.01% 552

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Advisors's SCLN Position: Q1 2016 in Review

Boston Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2016, closing a stake of 10,373 shares — an estimated $95K sold.

Boston Advisors first reported a position in SCLN in Q2 2013 and held it in 11 quarters. The position peaked at $813K in Q2 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

  • Boston Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Boston Advisors sold 10,373 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $95K.
  • Boston Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 11 quarters.
  • Boston Advisors's Sciclone Pharmaceuticals Inc position peaked at $813K in Q2 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Boston Advisors's 13F filing for Q1 2016, filed 20 Apr 2016.